Cheng-hsiang B. Lo

No. 325, Cheng Gong Rd, 114
Neihu, TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Comparative Effectiveness of Adjuvant XELOX Versus TS-1 Monotherapy After D2 Gastrectomy for Stage III Gastric Cancer: A Real-World Nationwide Cohort Study.

Comparative Effectiveness of Adjuvant XELOX Versus TS-1 Monotherapy After D2 Gastrectomy for Stage III Gastric Cancer: A Real-World Nationwide Cohort Study.

Journal: Life (Basel, Switzerland)

Published: April 17, 2026

Radiation-induced severe lymphopenia predicts distant metastasis in rectal cancer: dosimetric implications for immune-sparing radiotherapy.

Radiation-induced severe lymphopenia predicts distant metastasis in rectal cancer: dosimetric implications for immune-sparing radiotherapy.

Journal: Radiation oncology (London, England)

Published: July 20, 2025

Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma.

Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma.

Journal: BMC cancer

Published: April 12, 2025

Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis.

Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis.

Journal: EClinicalMedicine

Published: March 28, 2025

Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma.

Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma.

Journal: JCO precision oncology

Published: December 05, 2024

Response‑adapted involved site radiation therapy for hepatic marginal zone B‑cell lymphoma: A case report.

Response‑adapted involved site radiation therapy for hepatic marginal zone B‑cell lymphoma: A case report.

Journal: Oncology letters

Published: October 30, 2024

Primary Stereotactic Body Radiation Therapy for Breast Cancer Spinal Metastases.

Primary Stereotactic Body Radiation Therapy for Breast Cancer Spinal Metastases.

Journal: Clinical breast cancer

Published: September 24, 2024

Improving the prediction of patient survival with the aid of residual convolutional neural network (ResNet) in colorectal cancer with unresectable liver metastases treated with bevacizumab-based chemotherapy.

Improving the prediction of patient survival with the aid of residual convolutional neural network (ResNet) in colorectal cancer with unresectable liver metastases treated with bevacizumab-based chemotherapy.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: March 13, 2024

Stereotactic body radiotherapy for painful spinal metastases: a decade of experience at a single institution.

Stereotactic body radiotherapy for painful spinal metastases: a decade of experience at a single institution.

Journal: Journal of neurosurgery. Spine

Published: December 06, 2023

Vertebral fracture following primary stereotactic body radiation therapy for spinal bone metastases: a decade of experience.

Vertebral fracture following primary stereotactic body radiation therapy for spinal bone metastases: a decade of experience.

Journal: Journal of neurosurgery. Spine

Published: November 14, 2023

Corrigendum to "Guggulsterone inhibits migration and invasion through proteasomal and lysosomal degradation in human glioblastoma cells" [Eur. J. Pharmacol. 938 (2023) 175411].

Corrigendum to "Guggulsterone inhibits migration and invasion through proteasomal and lysosomal degradation in human glioblastoma cells" [Eur. J. Pharmacol. 938 (2023) 175411].

Journal: European journal of pharmacology

Published: November 12, 2023

Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.

Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.

Journal: European journal of radiology

Published: August 04, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026